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A b s t r a c t
Background: Atrial tachyarrhythmias are a leading source of morbidity and mortality after Fontan-type procedures and antiar-
rhythmic drug therapy is often ineffective in these patients.
Aim: To evaluate short- and long-term outcomes of radiofrequency current ablation for atrial tachycardia (AT) in patients after 
the Fontan procedure, and to report clinical, electrophysiological and electroanatomical characteristics of these arrhythmias. 
Methods: We retrospectively analysed data obtained in 8 patients (5 males, 3 females) after the Fontan procedure who 
underwent ablation for AT between 2002 and 2013. In order to compare the clinical impact of arrhythmia before and after 
ablation, we used the modified arrhythmia score, ranging from 0 (no arrhythmia activity) to 12 (very severe arrhythmia). In 
all patients, electroanatomical mapping using the CARTO system was performed, allowing semiquantification of low-voltage 
(< 0.5 mV) areas and scars. 
Results: Seven patients had an atriopulmonary connection and 1 patient had an extracardiac conduit. The mean patient 
age was 9.4 ± 3.1 years at the time of the Fontan procedure and 26.2 ± 4.6 years at the time of the first ablation. A total of 
18 ablations were performed with no complications, 1 to 4 (median 2.5) procedures per patient. In patients who had more 
than 1 ablation, the mean time from the first to the last procedure was 34.8 months (range 1–64 months). In individual pa-
tients, 1 to 4 (median 2.5) different ATs were observed, with the mean tachycardia cycle length of 334 ± 95 ms. In 6 patients, 
low-voltage area (< 0.5 mV) comprised 25–50% of the right atrium, and in two others it comprised 10–25% and < 10% of 
the right atrium, respectively. Seven procedures were fully successful (ablation of all ATs), 7 were partially successful (ablation 
of only some AT, including clinical arrhythmia, but not of all ATs) and 4 were unsuccessful (failed ablation of clinical AT). The 
mean procedural, fluoroscopy and ablation times were 176 ± 54.6, 13.7 ± 5.7 and 21.7 ± 11.9 min, respectively. Free-
dom from arrhythmia during the mean follow-up of 58.6 ± 46 months (range 11–127 months) since the last procedure was 
obtained in 4 patients. The median arrhythmia score after the last ablation was significantly reduced compared to baseline 
(4.5 vs. 8; p < 0.05). 
Conclusions: Catheter ablation of AT in patients after the Fontan procedure is safe but its acute and long-term efficacy is 
limited. Due to complex and extensive substrate, along with complex anatomy, recurrences are frequent and patients may 
require repeat ablation procedures. Suppression of arrhythmia is associated with an improved clinical status of the patients. 
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INTRODUCTION
The term “functionally single ventricle” refers to congenital 
heart disease (CHD) without two normally developed ven-
tricles or one of the atrioventricular valves, or when a repair 
surgery with creation of biventricular circulation is not possible 
due to atrioventricular valve straddling. 
The purpose of the Fontan procedure is to separate 
systemic and pulmonary circulation. In a Fontan circulation, 
systemic venous return is diverted directly to the pulmonary 
arteries, bypassing the ventricle. Inferior vena cava return to 
the pulmonary arteries is obtained by creation of an intraatrial 
lateral tunnel (LT) which connects the vena cava inferior with 
the right pulmonary artery and is formed partially from the 
atrial wall and partially from a patch [1]. Another technique 
that allows connecting the vena cava inferior with the right 
pulmonary artery without atrial involvement is an extracar-
diac conduit (ECC) [2]. In the past, the right atrium (RA) was 
connected to the pulmonary artery (PA) but this procedure, 
known as atriopulmonary (RA-PA) connection, is no longer 
performed due to frequent complications [3]. An invariable 
element of the Fontan procedure is bidirectional Glenn shunt, 
or end-to-side anastomosis of the vena cava superior with 
the right pulmonary artery, resulting in total cavopulmonary 
connection (TCPC) [4, 5]. 
Supraventricular tachyarrhythmias are a major complica-
tion of the Fontan circulation. Occurrence of atrial tachycardia 
(AT) in a patient after the Fontan procedure may result in 
a significant worsening of the clinical status, often leading to 
the development or worsening of heart failure, syncope, or 
even death (Fig. 1) [6, 7]. Persistent arrhythmia with rapid 
ventricular response may lead to impaired function of the 
single ventricle, and systolic and diastolic dysfunction of 
the single ventricle may in turn result in the development 
or worsening of the atrioventricular valve regurgitation. In 
addition, haemodynamic disturbances associated with AT 
lead to venous stasis and thus predispose to thrombosis [8]. 
Antiarrhythmic drug therapy is of a limited effectiveness, may 
result in clinically significant bradycardia, and may lead to 
further ventricular function impairment [9]. For these reasons, 
ablation of AT substrate is currently an important therapeutic 
option in this patient group.
The aim of the study was to evaluate short- and long-term 
outcomes of AT ablation in patients after the Fontan proce-
dure, and to report clinical, electrophysiological and electro-
anatomical characteristics of these arrhythmias.
METHODS
Study population
We retrospectively analysed data obtained in 8 patients 
(5 males, 3 females) after the Fontan procedure who un-
derwent ablation for drug-refractory AT between 2002 and 
2013. At the time of ablation, 7 patients had an RA-PA con-
nection  and 1 patient had TCPC with ECC.
Arrhythmia score
To allow objective assessment of the clinical importance of 
AT, we used the modified arrhythmia score which was previo-
usly proposed for the evaluation of patients with arrhythmia 
following surgery for CHD [10]. It is a sum of 4 components 
that describe and categorise: (1) maximum duration of the 
arrhythmia, (2) arrhythmia-related symptoms; (3) methods 
to terminate arrhythmia; and (4) antiarrhythmic therapy to 
prevent further episodes. Score values range from 0 (no 
arrhythmia activity) to 12 (very severe arrhythmia) (Table 1). 
Figure 1. Atrial tachycardia (AT) with rapid ventricular response in a patient after the Fontan procedure, manifesting with syn-
copes. Paper speed 50 mm/s. Rapid ventricular rate results from AT with the cycle length of about 300 ms and 1:1 conduction. 
P waves of the tachycardia are not clearly seen. In the initial part of the tracing, QRS complex widening to about 180 ms due to 
aberration is seen in the limb leads. In the later part of this tracing and in precordial leads, QRS duration is about 110 ms, and 
QRS complexes are characterised by a right bundle branch block morphology
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Use of this score allows comparisons of the severity of 
arrhythmia, arrhythmia-related symptoms and treatment 
used before and after the ablation. In the study group, we 
evaluated the modified arrhythmia score before the first and 
after the last ablation.
Electrophysiological testing and ablation
Before ablation, each patient gave written informed consent 
for the procedure, the wording of which was previously ac-
cepted by the local bioethics committee. Intracardiac leads 
were introduced through the femoral vessels. Twelve-lead 
surface electrocardiogram (ECG) and intracardiac electro-
grams were recorded using electrophysiology systems (EP 
MedSystems, West Berlin, NJ, USA, or Bard, Bard Electro-
physiology Division C.R. Bard, Inc. Lowell, MA, USA). An 
electroanatomic mapping system (CARTO, Biosense Webster, 
Inc., Diamond Bar, CA, USA) was also used during each pro-
cedure to create anatomic, potential, and activation maps. In 
each patient, we used a flexible 4-polar diagnostic catheter 
placed in a stable location, preferably the coronary sinus. In 
patients with RA-PA connection, leads were introduced to 
the atrium via the inferior vena cava, and in the patient with 
ECC using a retrograde approach through the aorta, ventricle, 
and the atrioventricular valve. Following lead placement, 
heparin was administered in an initial dose of 50–100 U/kg, 
followed by 1000 U each hour. Two ablation procedures 
were performed using an 8 mm tip catheter (Navistar, DS, 
Biosense Webster, Diamond Bar, CA, USA), and the others 
using a 3.5 mm irrigated tip catheter (Navistar, Thermocool, 
Biosense Webster, Diamond Bar, CA, USA). Maximum power 
during the ablation did not exceed 60 Watt when using the 
8 mm tip catheter and 42 Watt when using the irrigated tip 
catheter. The extent of the ablation depended on the clini-
cal situation and was left to the operator’s discretion. First, 
an atrial map was created. In patients with persistent AT at 
baseline, the CARTO map was created during the arrhythmia. 
The aim of mapping was to visualise the reentry circuit or 
the focal origin of the focal tachycardia, and to visualise scars 
and low-amplitude areas (Figs. 2, 3). In patients with sinus 
rhythm at baseline, the potential map was created during 
pacing, and programmed stimulation was then attempted 
to induce tachycardia. The choice of sites for ablation was 
based on the analysis of potential and activation maps along 
with entrainment pacing. During the procedure, we aimed to 
terminate the arrhythmia by ablation. If this was not possible, 
antitachycardia pacing was used at the end of the procedure, 
followed by electrical cardioversion if pacing was ineffective. 
In patients in whom tachycardia was terminated during radio-
frequency (RF) current application, following the ablation we 
evaluated whether the arrhythmia remained inducible by 
performing programmed stimulation (up to 2 extrastimuli) 
and rapid pacing up to the cycle length of 250–220 ms or 
the atrial refractory period. In patients in whom the ablation 
of the cavo-tricuspid isthmus was performed, the endpoint 
was to obtain a conduction block in this area. Similarly, if 
the ablation was performed between two non-conducting 
areas (e.g., scar-scar or scar-conduit), we also aimed to create 
a conduction block in these areas. 
Electroanatomical evaluation of the atrium
To evaluate the degree of right atrial damage, we used 
CARTO maps to estimate the size of scar and low-amplitude 
areas. The evaluation was made visually in 4 perpendicular 
views (anterior, left lateral, right lateral, and posterior) for 
the cut-off points of < 0.5 mV and < 1 mV. We determined 
whether areas described by the above parameters comprised 
the following proportions of the atrial size: < 10%, 10–25%, 
25–50%, 50–75%, or > 75% (Figs. 2, 3). Due to semiquan-
titative nature of this assessment, evaluation was performed 
twice several days apart. If the results obtained during these 
Table 1. Modified arrhythmia score
Type of arrhythmia Score Termination of arrhythmia Score
No documented arrhythmia 0 Spontaneous 0
Unsustained arrhythmia 1 Drugs 1
Sustained arrhythmia 2 Single cardioversion 2
Persistent arrhythmia 3 Multiple cardioversions 3
Symptoms related to arrhythmia Score Antiarrhythmic therapy Score
Asymptomatic arrhythmia 0 No AA drugs/digoxin 0
Palpitation 1 Class II or IV (BB or CA) 1
Syncope/CHF/thrombosis/cyanosis 2 Class I or III 2
Cardiac arrest 3 Adverse effects of amiodarone 3
The modified arrhythmia score is a sum of four components that describe and categorize: (1) maximum duration of the arrhythmia, (2) arrhyth-
mia-related symptoms; (3) methods to terminate arrhythmia; and (4) antiarrhythmic therapy to prevent further episodes. Each component is 
scored from 0 to 3, and the maximum score is 12; AA — antiarrhythmic; BB — beta-blocker; CA — calcium antagonist; CHF — congestive heart 
failure
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tachycardia was considered reentrant if > 75% of AT cycle 
could be mapped and/or entrainment pacing confirmed the 
reentrant nature of the arrhythmia. Focal arrhythmia was 
defined as regular or irregular tachycardia originating within 
a limited area, characterised by a concentric activation within 
the atria. If more than one tachycardia was identified, dif-
ferent AT morphologies were diagnosed if: (1) a change in 
two occasions differed, the result with less low-amplitude 
areas was considered the final assessment.
Characteristics of the recorded arrhythmia
For all clinical and induced arrhythmias, we attempted to map 
its reentry circuit or the focal origin using the electroanatomical 
mapping system and also entrainment pacing if possible. The 
Figure 3. Atrial potential and activation maps during tachycardia. Colour-coded right atrial potential (A) and activation (B) maps 
in the right lateral view in a patient with atrial tachycardia (AT). Scar areas are shown in grey. A. The reentry circuit of an AT with 
the cycle length of 320 ms was mapped entirely to the lateral wall of the right atrium. Red indicates the earliest (–158 ms) and 
pink the latest (155 ms) activation. Blue dots indicate places where dual potentials were recorded, consistent with functional 
conduction block. Yellow dots indicate sites of entrainment pacing. Burgundy dots indicate places of radiofrequency current 
application; B. The reentry circuit of the tachycardia was mapped to low-amplitude (< 0.5 mV) area adjacent to scar
A B
Figure 2. Atrial potential map. Colour-coded atrial potential map in the left anterior oblique (LAO; A) and the right anterior 
oblique (RAO; B) views. Colour coding scale is shown to the right. Areas with the voltage of < 0.5 mV are coded red, and those 
with the voltage of > 1 mV are coded pink. Areas with the voltage in the range of 0.5–1.0 mV are coded with the remaining 
colours. In the views showed, most of the right atrium shows the voltage of < 1 mV, and areas with the voltage of < 0.5 mV 
comprise up to 50% of the atrial area
A B
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the P/F wave morphology was observed in the surface ECG; 
(2) a change in the direction of activation/origin site of the 
tachycardia was observed; or (3) a significant change in the 
cycle length (± 20 ms) was seen in association with a change 
of the reentry circuit/focal origin of the tachycardia.
Immediate ablation success
The ablation procedure was considered effective if all ATs 
were terminated, both clinical and induced, and no persis-
tent arrhythmia was induced during the electrophysiological 
study (EPS) after the procedure. The ablation procedure was 
considered partially effective if clinical AT was terminated but 
not all tachycardia induced during EPS could be terminated. 
The ablation procedure was considered ineffective if clinical 
AT could not be terminated. 
Long-term outcomes
Following the procedure, the patients were monitored for ab-
lation efficacy at 4–12 weeks and then every 3–6 months. Dur-
ing the follow-up visits, ECG was performed, along with Holter 
monitoring at least once a year. In addition, conventional ECG 
and/or Holter monitoring was performed whenever the patient 
reported recurrent palpitation. The arrhythmia recurrence 
was defined as recurrent atrial flutter, AT or atrial fibrillation 
recorded in ECG or each palpitation lasting more than 3 min if 
it occurred past 6 weeks after the ablation and was of a similar 
nature to the symptoms occurring before the ablation. If dic-
tated by the clinical situation, e.g. tachycardia with significant 
symptoms persisted after the ablation, a repeated ablation was 
performed before 6 weeks after the previous ablation (Table 2, 
patient No. 3). Follow-up echocardiographic examination was 
performed after each ablation procedure and at least once 
a year during long-term follow-up.
Statistical analysis
Continuous variables were reported as mean values ± stand-
ard deviation. For non-normally distributed variables, we also 
reported medians and ranges. Quantitative variables were 
compared using the Wilcoxon test. P < 0.05 was considered 
statistically significant. Statistical analysis was performed using 
the Statistica 5.0 software (StatSoft, Inc., Tulsa, OK, USA). 
RESUlTS
Detailed data on the study population and ablation out-
comes are given in Tables 2 and 3. The mean patient age 
was 9.4 ± 3.1 years at the time of the Fontan procedure and 
26.2 ± 4.6 years at the time of the first ablation. The mean 
time from the Fontan procedure to the first ablation was 
16.5 ± 4.4 years. A total of 18 ablations were performed with 
no complications, 1 to 4 (median 2.5) procedures per patient. 
Table 2. Clinical data and treatment outcomes
Patient  
no.







































1 M 20 12 8 DRV ECC 1 – 127 1 episode of AT 
requiring electrical 
cardioversion (sotalol)
2 M 21 4 17 DLV RA-PA 3 9 90 No arrhythmia 
(sotalol)
3 F 28 10 18 DLV RA-PA# 2 1 102 No arrhythmia 
(sotalol)
4 F 23 6 17 DLV RA-PA 3 58 79 Permanent AF
5 M 29 12 17 DLV RA-PA 4 42 11 No arrhythmia (BB)
6 M 27 11 16 DLV RA-PA# 1 – 19 AT episodes requir-
ing admission at 
5 months after abla-
tion (amiodarone)
7 F 34 10 24 DLV RA-PA# 4 64 29 Permanent AF/death
8 M 26 11 15 DLV RA-PA 1 – 13 No arrhythmia
#Conversion to ECC after the last ablation; AF — atrial fibrillation; AT — atrial tachycardia; BB — beta-blocker; DLV — dominant left ventricle; 
DRV — dominant right ventricle; ECC — extracardiac conduit; F — female; M — male; RA-PA — atriopulmonary connection
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In patients who had more than 1 ablation, the mean time 
from the first to the last procedure was 34.8 months (range 
1–64 months). In individual patients, 1 to 4 (median  2.5) 
different ATs were observed during the procedure, with the 
mean tachycardia cycle length of 334 ± 95 ms. The area of 
significant damage with low voltage of < 0.5 mV comprised 
25–50% of the right atrium in 6 patients, and < 10% of the 
common atrium in the single patient with ECC. In all patients 
with RA-PA connections, voltage < 1 mV was recorded over 
50–75% of the atrium. 
Seven procedures were fully successful, 7 were par-
tially successful, and 4 were unsuccessful. The mean pro-
cedural, fluoroscopy and RF current application times were 
176 ± 54.6, 13.7 ± 5.7 and 21.7 ± 11.9 min, respectively. 
Freedom from arrhythmia during the mean follow-up of 
58.6 ± 46 months (range 11–127 months) since the last 
procedure was obtained in 4 patients. The median arrhythmia 
score was 4.5 after the last ablation compared to 8 before the 
first ablation (p < 0.05) (Fig. 4).
Conversion to ECC was performed in 3 patients after the 
last ablation procedure. In this subgroup, 1 patient (No. 3) 
remains without significant arrhythmia, 1 patient (No. 7) 
died in the periprocedural period, and in the remaining 
patient (No.  6), with persistent tachycardia refractory to 
cardioversion at baseline, arrhythmia did not recur during 
short- and mid-term follow-up, which resulted in a significant 
improvement of the clinical status and an increase in the 
ventricular ejection fraction from 30% to 60%. Five months 
after the ablation and 1 month after conversion to ECC 
with intraprocedural ablation, episodes of tachycardia with 
rapid ventricular rate developed, and the patient required 
hospital admission and electrical cardioversion. In this 
patient access to the atrium is very difficult due to the use 
of ECC without fenestration and the presence of a mitral 
Figure 4. Modified arrhythmia score values in individual pa-
tients before and after ablation
valve prosthesis. The patient receives amiodarone which is 
partially effective.
DISCUSSION
Atrial tachycardias are a leading source of morbidity and 
mortality in patients after Fontan-type procedures [6, 7, 11]. 
Among patients with RA-PA connection that was performed 
in the past, the proportion of patients with supraventricular 
arrhythmia at 20 years after the surgery may be as high as 50% 
[12, 13]. In case of LT that was performed during a later period 
and currently preferred ECC, these proportions are 6–35% 
and 2–28%, respectively [14–16]. Thus, studies suggest that 
the incidence of arrhythmia is lower in patients with LT and 
ECC compared to those with RA-PA connection. Of note, 
however, the duration of long-term follow-up in patients with 
LT and ECC is significantly shorter compared to those with 
RA-PA connection. Thus, comparisons of arrhythmia incidence 
in these patient groups and evaluation of potential advantage 
of LT and ECC over RA-PA connection require further stud-
ies. At the same time, the access to the arrhythmia substrate 
within the atrium may be much more difficult with these two 
latter modifications of the Fontan procedure, particularly in 
case of ECC without fenestration, requiring puncture of the 
tunnel or conduit, or a retrograde approach through the 
aorta. This may render effective ablation procedure much 
more difficult or impossible [17, 18]. An example of these 
difficulties is our patient No. 6 after conversion to ECC. For 
these reasons, it seems justified to perform a fenestration 
between the conduit and the atrium in all patients with ECC 
if technically and clinically (degree of desaturation) feasible. 
In case of a retrograde approach through the aorta, lead 
manoeuvring in the atrium is very difficult and some areas 
may be impossible to reach. Remote magnetic navigation 
systems are a significant improvement in such a situation, as 
they allow reaching nearly all atrial areas, which translates to 
better ablation outcomes [19]. Unfortunately, such systems 
are currently unavailable in Poland. 
Our results indicate limited short-term efficacy of the 
procedures and a high rate of arrhythmia recurrences fol-
lowing AT ablation in this patient group. This led to a high 
number of ablation procedures despite a small number of 
patients. However, the mean interval between subsequent 
ablation procedures was quite long, which indicates at 
least temporary efficacy of the procedures and may sug-
gest progressive atrial remodelling and disease progression. 
Similar observations regarding progressive atrial remodelling 
were made by Correa et al. [20] who performed ablation in 
32 patients with a Fontan-type circulation in whom TCPC 
was performed.
Literature data indicate that short-term efficacy of 
ablation in patients after the Fontan procedure is 43–83%, 
and the recurrence rate during long-term follow-up (up 
to 4 years) is 32–76% [10, 20–22]. In a recent study that 
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reported ablation outcomes in 19 patients after the Fontan 
procedure, only 3 (15%) patients were free from arrhythmia 
recurrence at 4 years of follow-up [22]. These results are 
clearly worse compared to patients with other CHD, both 
simple and complex [22]. One reason for limited efficacy of 
ablation in patients after the Fontan procedure, particularly 
those with RA-PA connection, is significant right atrial dilation 
along with extensive fibrosis and wall thickening. The degree 
of atrial enlargement correlated with the extent of structural 
damage which may be visualised using electroanatomical 
mapping systems as scar and low amplitude areas [23, 24]. 
In the studies by Yap et al. [23] and Abrams et al. [24], the 
proportion of right atrial areas with a voltage of < 0.5 mV 
was 44% and 38%, respectively. These values were signifi-
cantly higher compared to patients after repair of other CHD. 
Our findings are consistent with these observations. These 
extensive damage areas are a result of scarring following 
previous surgery on one hand, and an increased right atrial 
pressure on the other hand, particularly in case of RA-PA 
connection. Atrial wall thickening and fibrosis secondary to 
elevated atrial pressure may render transmural damage more 
difficult to obtain during the ablation procedure which also 
translates to less favourable treatment outcomes. High atrial 
pressure persisting after the ablation may lead to further 
damage which may be an origin of new arrhythmia or sustain 
a reentry circuit [20, 22]. In addition, high desaturation be-
fore the Fontan procedure may damage cardiomyocytes and 
alter gene expression, leading to permanent proarrhythmic 
structural and functional changes [25].
Another reason for limited ablation efficacy may be mul-
tiple reentry circuits and arrhythmia foci in individual patients, 
as well as their atypical location, i.e. outside the cavotricuspid 
isthmus [22, 26]. In our study group, the median number of 
different AT morphologies was 2.5 per patient. The presence 
of several reentry circuits of different foci of tachycardia makes 
their identification and effective ablation much more difficult. 
Despite these limitations, ablation as a component 
of comprehensive treatment approach may contribute to 
improvement of the clinical status in treated patients. This 
does not necessarily mean that arrhythmia is completely 
suppressed and/or drug treatment can be stopped. However, 
a significant reduction of the number and severity of tachy-
cardias, leading to a reduced need for hospitalisation and 
cardioversion, translates to an improved patient well-being. 
Thus, evaluation of the treatment outcomes in patients after 
a surgery for CHD should be based on several parameters or 
multicomponent indexes, such as the proposed arrhythmia 
score [10]. On the other hand, such score does not always 
show all benefits from the ablation. The example could be 
our patient No. 1 who remained free from clinically significant 
arrhythmia for several years after the ablation. The reason for 
high arrhythmia score during long-term follow-up was a single 
episode of tachycardia with significant clinical symptoms 
requiring cardioversion that occurred several years after the 
ablation. Somewhat different situation occurred in our patient 
No. 6, in whom arrhythmia recurred several months after 
the ablation but the procedure allowed effective treatment 
of persistent tachycardia with rapid ventricular rate, leading 
to impaired ventricular function. 
Finally, it should be noted that presence of ATs in patients 
after a repair surgery for CHD, and particularly in patients 
after the Fontan procedure, is associated with a relatively 
high mortality of about 1.8% per year [10, 11]. Such a high 
mortality indicates low haemodynamic compensation capa-
bilities in the setting of atrial tachyarrhythmia in patients with 
congenital heart disease.
Limitations of the study
The study group was small and statistical analysis of such 
a small samples is prone to errors. The study population was 
not entirely homogenous, with RA-PA connection in 7 patients 
and TCPC with ECC in 1 patient. Our results and conclusions 
may refer mostly to patients with RA-PA connection.
CONClUSIONS
Catheter ablation of AT in patients after the Fontan surgery is 
safe but its acute and long-term efficacy is limited due to com-
plex and extensive substrate along with complex anatomy. 
For these reasons, good outcomes may require performing 
more than 1 ablation procedure. Suppression of arrhythmia 
is associated with an improved clinical status of the patients. 
Conflict of interest: none declared
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S t r e s z c z e n i e
Wstęp: Częstoskurcze przedsionkowe (AT) są jedną z wiodących przyczyn chorobowości i śmiertelności u pacjentów po 
operacji Fontana, a skuteczność terapii lekami antyarytmicznymi w tej grupie chorych jest z reguły ograniczona. 
Cel: Celem pracy była ocena wyników bezpośrednich i odległych ablacji AT u pacjentów po operacji Fontana oraz ocena 
charakterystyki klinicznej, elektrofizjologicznej i elektroanatomicznej arytmii.
Metody: Retrospektywną analizą objęto dane 8 pacjentów (5 mężczyzn, 3 kobiety) po operacji Fontana kierowanych na 
ablację w latach 2002–2013 z powodu AT. Istotność kliniczną i nasilenie arytmii przed i po ablacji oceniono za pomocą 
zmodyfikowanego wskaźnika arytmicznego. Jest on sumą czterech składowych wartościujących, takich jak: 1) maksymalny 
czas trwania arytmii, 2) objawy związane z arytmią, 3) metody przerywania arytmii, 4) terapia antyarytmiczna konieczna 
do zapobiegania napadom. Wskaźnik ten przyjmuje wartości od 0 (bez istotnej arytmii) do 12 punktów (ciężka arytmia). 
U wszystkich pacjentów zabiegi ablacji wykonywano z zastosowaniem systemu CARTO, co pozwoliło na półilościową ocenę 
wielkości obszarów niskoamplitudowych (< 0,5 mV) i blizn w obrębie przedsionka.
Wyniki: U 7 chorych obecne było połączenie prawy przedsionek–tętnica płucna, a u 1 chorego — tunel zewnątrzsercowy. 
Średni wiek pacjentów w trakcie wykonania operacji Fontana wynosił 9,4 ± 3,1 roku, a w trakcie wykonywania pierwszej 
ablacji — 26,2 ± 4,6 roku. W badanej grupie wykonano łącznie 18 ablacji bez istotnych powikłań, 1–4 ablacje/chorego; me-
diana 2,5. U pacjentów, u których przeprowadzono więcej niż 1 ablację, odstęp czasu między pierwszym a ostatnim zabiegiem 
wynosił średnio 34,8 miesiąca (zakres 1–64 miesiące). W trakcie zabiegów u poszczególnych pacjentów obserwowano od 
1 do ponad 4 różnych morfologii częstoskurczów (mediana 2,5). Średni cykl AT wynosił 334 ± 95 ms. U 6 pacjentów obszary 
istotnego uszkodzenia z amplitudą < 0,5 mV zajmowały 25–50% powierzchni prawego przedsionka, a u dwóch kolejnych osób, 
odpowiednio, 10–25% i < 10% jego powierzchni. Siedem ablacji było w pełni skuteczne (usunięto wszystkie AT — kliniczne 
i wywołane stymulacją), kolejne 7 ablacji było częściowo skuteczne (nie usunięto wszystkich arytmii, ale usunięto kliniczny 
AT), a 4 ablacje były nieskuteczne (nie usunięto klinicznego AT). Średnie czasy zabiegu, skopii rentgenowskiej i dostarczania 
energii o częstotliwości radiowej wynosiły odpowiednio: 176 ± 54,6; 13,7 ± 5,7 i 21,7 ± 11,9 minut. W obserwacji odległej, 
średnio 58,6 ± 46 (zakres 11–127) miesięcy po ostatniej ablacji, u 4 pacjentów nie stwierdzono arytmii. Mediana wskaźnika 
arytmicznego przed pierwszą ablacją wynosiła 8 punktów, a po ostatniej ablacji — 4,5 punktu (p < 0.05). 
Wnioski: Ablacja AT u pacjentów po operacji Fontana jest zabiegiem bezpiecznym, ale jej skuteczność bezpośrednia i od-
legła jest ograniczona. Wynika to z rozległego i złożonego substratu oraz trudnych warunków anatomicznych. Uzyskanie 
dobrych efektów może wymagać wykonania więcej niż jednej ablacji. Opanowanie arytmii przyczynia się do poprawy stanu 
klinicznego pacjentów.  
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